NeuroXess raises RMB 700 million for brain-computer interfaces

Chinese brain-computer interface company NeuroXess has raised RMB 700 million in a Series B round led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital, according to TechNode. The company says the new funding will support multicentre clinical trials, regulatory submissions, manufacturing capacity and development of next-generation products. NeuroXess develops implantable flexible brain-computer interface systems that combine electrodes with wireless power and data transmission. Its technology is intended to support movement and speech decoding, as well as control of external devices. The company’s English-language site describes it as a life-science business focused on implantable flexible BCI technology.

The funding arrives as NeuroXess pushes towards larger clinical and manufacturing programmes. TechNode reports that the company has completed 65 clinical cases and began a registration trial involving nearly 20 hospitals in July. It is also building a 14,300-square-metre manufacturing facility with planned annual capacity of 10,000 systems. NeuroXess’s recent public material has highlighted its Triple-F system: fully implanted, fully wireless and fully functional. In a September update, the company described experiments combining the system with AI models, 3D printing and smart glasses to help a participant with high-level tetraplegia express creative intent, operate devices and control elements of a smart environment.

Those targets matter because implantable BCI research is moving from laboratory demonstrations towards the slower work of proving safety, reliability and usefulness across clinical settings. Raising capital does not itself establish that a device is ready for widespread medical use, but it can fund the evidence-gathering needed to reach that point.

Our opinion

The most interesting part of this announcement is its emphasis on the unglamorous middle of BCI development. A funding round can make brain-computer interfaces sound close to a consumer breakthrough, but the harder test is repeatable clinical evidence, dependable manufacturing and regulatory scrutiny. NeuroXess is putting money into those bottlenecks. The RMB 700 million raise is significant without being proof that the technology is ready for everyday use; the next milestones are clinical data, registration progress and whether planned manufacturing capacity turns research demonstrations into approved systems.